PubMed

Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.

Shastri YM, Povse N, Schröder O, Stein J.

Clin Lab. 2008;54(9-10):389-90. No abstract available. PMID: 19097497 [PubMed - indexed for MEDLINE]Related articles

Prospective comparative evaluation of an office-based rapid immunological test with a Guaiac-based fecal occult blood test for colorectal cancer screening in general population with average-risk.

Shastri YM, Loitsch S, Nowak R, Povse N, Stein J.

Clin Lab. 2008;54(9-10):385-7. No abstract available. PMID: 19097496 [PubMed - indexed for MEDLINE]Related articles

Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.

Shastri YM, Bergis D, Povse N, Schäfer V, Shastri S, Weindel M, Ackermann H, Stein J.

Am J Med. 2008 Dec;121(12):1099-106.PMID: 19028207 [PubMed - indexed for MEDLINE]Related articles

Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.

Shastri YM, Stein JM.

Br J Cancer. 2008 Oct 21;99(8):1366; author reply 1367. Epub 2008 Sep 30. No abstract available. PMID: 18827821 [PubMed - indexed for MEDLINE]Related articlesFree article

PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells.

Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schröder O, Stein J.

Carcinogenesis. 2008 Jul;29(7):1407-14. Epub 2008 Jun 9.PMID: 18544567 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.

Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, Mössner J, Stein JM.

Am J Gastroenterol. 2008 Jun;103(6):1496-504. Epub 2008 May 28.PMID: 18510609 [PubMed - indexed for MEDLINE]Related articles

New introducer PEG gastropexy does not require prophylactic antibiotics: multicenter prospective randomized double-blind placebo-controlled study.

Shastri YM, Hoepffner N, Tessmer A, Ackermann H, Schroeder O, Stein J.

Gastrointest Endosc. 2008 Apr;67(4):620-8.PMID: 18374024 [PubMed - indexed for MEDLINE]Related articles

Endoscopic feeding tube placement in patients with cancer: a prospective clinical audit of 2055 procedures in 1866 patients.

Shastri YM, Shirodkar M, Mallath MK.

Aliment Pharmacol Ther. 2008 Apr;27(8):649-58. Epub 2008 Jan 22.PMID: 18221411 [PubMed - indexed for MEDLINE]Related articles

New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?

Shastri YM, Stein JM.

Br J Cancer. 2007 Dec 3;97(11):1595-6; author reply 1597. Epub 2007 Oct 23. No abstract available. PMID: 17955052 [PubMed - indexed for MEDLINE]Related articlesFree article

Quantitative immunochemical fecal occult blood test for diagnosing colorectal neoplasia.

Shastri YM, Stein J.

Ann Intern Med. 2007 Oct 2;147(7):522-3; author reply 523. No abstract available. PMID: 17909220 [PubMed - indexed for MEDLINE]Related articlesFree article

Autologous blood as a submucosal fluid cushion for endoscopic mucosal therapies: results of an ex vivo study.

Shastri YM, Kriener S, Caspary WF, Schneider A.

Scand J Gastroenterol. 2007 Nov;42(11):1369-75.PMID: 17852858 [PubMed - indexed for MEDLINE]Related articles

Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening.

Shastri YM, Stein J.

World J Gastroenterol. 2007 May 21;13(19):2768-9. No abstract available. PMID: 17569153 [PubMed - indexed for MEDLINE]Related articlesFree article

Liver biochemistry profile, significance and endoscopic management of biliary tract complications post orthotopic liver transplantation.

Shastri YM, Hoepffner NM, Akoglu B, Zapletal C, Bechstein WO, Caspary WF, Faust D.

World J Gastroenterol. 2007 May 28;13(20):2819-25.PMID: 17569117 [PubMed - indexed for MEDLINE]Related articlesFree article

Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.

Shastri YM, Naumann M, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein JM.

Int J Cancer. 2006 Dec 1;119(11):2651-6.PMID: 16929517 [PubMed - indexed for MEDLINE]Related articles

Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.

Hoepffner N, Shastri YM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein J.

Aliment Pharmacol Ther. 2006 Jan 1;23(1):145-54.PMID: 16393292 [PubMed - indexed for MEDLINE]Related articlesFree article

Total parenteral nutrition.

Mohandas KM, Shastri YM, Shirodkar M.

Natl Med J India. 2003 Jan-Feb;16(1):29-33. Review.PMID: 12715955 [PubMed - indexed for MEDLINE]Related articles

Acute hepatitis E due to travel to endemic area.

Shastri YM, Mohandas KM.

Indian J Gastroenterol. 2002 May-Jun;21(3):121-2. No abstract available. PMID: 12118929 [PubMed - indexed for MEDLINE]Related articles

Enteral nutrition by tube feeding in adults.

Mohandas KM, Shastri YM, Shirodkar M.

Natl Med J India. 2001 Sep-Oct;14(5):285-9. Review.PMID: 11767223 [PubMed - indexed for MEDLINE]Related articles